Clinical and molecular biology findings have led to the identification of tumour overexpressing HER2 (HER2+) as a distinct subset (comprising 20--25%) of breast carcinomas ([Slamon *et al*, 1989](#bib13){ref-type="other"}; [Ross and Fletcher, 1998](#bib11){ref-type="other"},[1999](#bib12){ref-type="other"}; [Ménard *et al*, 2002](#bib5){ref-type="other"}). This subgroup is characterised by a high aggressiveness ([Ferrero-Pous *et al*, 2000](#bib3){ref-type="other"}) and responsiveness to chemotherapy ([Ménard *et al*, 1999b](#bib7){ref-type="other"}). Since HER2-positivity has been associated with hormone independence due to the absence of expression of hormone receptors and unresponsiveness to tamoxifen ([Pietras *et al*, 1995](#bib9){ref-type="other"}; [Carlomagno *et al*, 1996](#bib2){ref-type="other"}), we hypothesised that hormonal risk factors may not influence HER2-positive tumours. If this is the case, the proportion of HER2-positive tumours as part of all tumours should be higher in the protected subgroup than in the unprotected ones.

To test this hypothesis, in a large surgical database of breast carcinomas at the National Cancer Institute of Milan from 1968 to 1979, we analysed the frequency of HER2-positive tumours, determined by immunohistochemistry, according to parity and age at menarche and at menopause.

PATIENTS AND METHODS
====================

Two series of consecutive patients treated at the Istituto Nazionale Tumori in Milan, Italy, for primary breast carcinoma were considered: first, 1211 patients who underwent surgery in 1968--1969 and received no further treatment ([Rilke *et al*, 1991](#bib10){ref-type="other"}) and second, 717 patients operated in 1978--1979 and who then received adjuvant chemotherapy ([Ménard *et al*, 1999a](#bib6){ref-type="other"}). The two series were very similar as concerned age at diagnosis, age at menarche, age at menopause, percent of premenopausal cases, number of children, nulliparous cases ([Table 1](#tbl1){ref-type="table"} Table 1Characteristics of the two cohorts included in the analysis **First seriesSecond seriesParameter1211 patients717 patients**Mean age at diagnosis (range)55 (21--81)1211^a^53 (25--84)717^a^Mean age at menarche (range)13 (10--20)1002^a^13 (7--19)690^a^Mean age at natural menopause (range)49 (30--62)649^a^48 (27--77)401^a^Frequency of premenopausal cases39%1211^a^43%717^a^Mean number of children (range)1.6 (0--8)970^a^1.8 (0--11)685^a^Frequency of nulliparous cases22%970^a^22%685^a^Frequency of HER2-positivity23%1211^a^23%717^a^[^1]). Only natural menopause was considered. Immunocytochemical staining was retrospectively carried out on Bouin-fixed, paraffin-embedded tissue using a polyclonal antibody against HER2-specific peptide (kindly provided by DJ Slamon), for the first series and anti-HER2 CB11 (1 : 10 dilution, Ylem, Avezzano, AQ, Italy) for the second series. Both antibodies revealed a 23% of HER2-positivity and an overlapping staining on consecutive slides stained with these two reagents ([Mezzelani *et al*, 1999](#bib8){ref-type="other"}).

The proportion of HER2-positive tumours was analysed, according to parity (1655 cases) and age at menarche (1692 cases) and at menopause (1050 cases). The subgroup with 0 or 1 child, and the subgroups of \<12 or \<45, respectively, for age of menarche and age of menopause were considered as control group (OR=1). The expected proportions (EP) of HER2-positivity were calculated assuming that HER2-positive tumours are not affected by hormonal risk factors and using the mean odds ratios (OR) reported for parity, ages at menarche and menopause ([Brinton *et al*, 1988](#bib1){ref-type="other"}; [Vatten and Kvinnsland, 1992](#bib14){ref-type="other"}; [Kelsey *et al*, 1993](#bib4){ref-type="other"}).

Expected proportions were defined as HER2-positive frequency of control group divided by mean OR reported in the literature for the risk group considered. Differences in proportions were analysed using the *χ*^2^ test.

RESULTS
=======

The first step in the analysis considered the effect of parity on HER2-positive breast cancer risk. The proportion of HER2-positive tumours was found to vary from 20.9% in the group with zero or one child, to 23.8% in the group with two or three children, up to 30.5% for women with more than three children ([Table 2](#tbl2){ref-type="table"} Table 2Frequency of HER2-positivity in primary breast carcinomas according to parity, ages at menarche and menopause of the patients**GroupsNo. of casesNo. of HER2+ casesObserved % HER2+OR Mean from literatureExpected % HER2+ considering no protection for HER2+ tumours***Parity*      0--180516820.9120.9 2--370916923.8\*0.9522.0 \>31414330.5\*0.7527.9      *Menarche*      \<122475321.5121.5 12--1380618422.8---  \>1363915824.70.8525.2      *Menopause*      \<451944523.2123.2 45--492986822.8---  \>4955812021.51.219.3\**P*=0.03 by *χ*^2^. OR=Odds ratio.     ). The significant increase of frequency (*P*=0.03, *χ*^2^-test) of HER2-positive tumours, according to the parity, suggests that this factor protects only the HER2-negative tumours. Accordingly, assuming protection only for the HER2-negative tumour subset and using the ORs as described in Patients and Methods for parity, the expected proportions of HER2-positivity would be of 20.9, 22.0 and 27.9% in the respective groups, that is, quite similar to the observed frequencies ([Table 2](#tbl2){ref-type="table"}).

The two other hormonal risk factors for breast carcinomas recorded in our database, that is, ages at menarche and menopause, also appear to have a protective impact only on HER2-negative tumours. In fact, an increased HER2-positive tumour proportion was observed with increased age at menarche, which is associated with decreased risk, and a decrease in HER2-positivity was observed with increased age at menopause, which is associated with increased risk ([Table 2](#tbl2){ref-type="table"}). Again using the estimated ORs and assuming protection only for HER2-negative tumours, the expected frequencies of HER2-positivity are in the range of the observed ones ([Table 2](#tbl2){ref-type="table"}).

DISCUSSION
==========

Altogether our analyses suggest that the three hormone-related risk factors analysed seem to protect only HER2-negative tumour subset. These results may be interpreted also as opposite to a promoting effect of hormone-related risk factors for the HER2-positive subgroup. Indeed, some clinical data ([Carlomagno *et al*, 1996](#bib2){ref-type="other"}) have suggested a detrimental effect of tamoxifen treatment in patients with HER2-positive tumours.

To date, the majority of risk factors for breast carcinomas identified are related to hormones. Identification of other risk factors, specific for the onset of HER2-positive tumours might be hampered by a clouding effect of HER2-negative tumours, which represent the great majority of breast carcinomas. Indeed, as long as HER2-positive tumours, which represent only 25% of cases and therefore of little weight among all breast carcinomas, are analysed together with the negative ones, it will be difficult to sort out risk factors for HER2-positive tumours.

In conclusion, our study suggests that HER2-negative and -positive tumour subsets are influenced differently by breast carcinoma hormone-related risk factors. To confirm these data, a cohort study specifically addressing the role of hormone risk-factors for breast cancer with respect to HER2 status is going on.

[^1]: Number of patients considered for series.
